Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension

Next Previous
Trial Profile

Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder; Urge incontinence
  • Focus Therapeutic Use

Most Recent Events

  • 29 Sep 2009 Results presented at the 39th Annual Meeting of the International Continence Society.
  • 16 May 2009 Results have been presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.
  • 27 Apr 2009 Results in women have been presented at the annual conference of the American Urological Association, according to a Waston Pharmaceutical's media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top